Clinical trials: Diabetic Complication
Diabetic Retinopathy, Macular Edema
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.
- Trial name
- NCT01476449
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Vitreous Associates of Florida
Pain
A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients.
- Trial name
- NCT00580294
- Testing
- Oxymorphone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diabetic Retinopathy
Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
To determine the safety and efficacy of intravitreal Aflibercept (Eylea) injection in patients with diabetic retinopathy in the prevention of macular edema following cataract surgery.
- Trial name
- PROMISE (NCT01988246)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rishi Singh
Retinal Disease
Assessment of Novel Intraocular Injection Guide
To determine if a novel intraocular injection guide (IIG) reduces patient discomfort during and after intravitreal injections.
- Trial name
- NCT02315170
- Testing
- intraocular injection guide, standard lid speculum
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Diabetic Foot
BE Study of Metformin GSK 500mg
A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fasting condition. It is a pivotal study.
- Trial name
- BA/BE 173/11 (NCT01710527)
- Testing
- Metformin 500mg, Glucophage 500mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetic Macular Edema
OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits
The purpose of this protocol is to determine whether point of care optical coherence tomography (OCT) imaging combined with an OCT-guided retinal referral algorithm at primary diabetes care visits increases rates of retina…
- Conditions
- Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- DME FOUND (NCT01875783)
- Testing
- OCT imaging
- Where
- 4 sites in United States
- Volunteers
- 385 people
- Sponsor
- Joslin Diabetes Center
Diabetic Neuropathy, Painful
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.
- Trial name
- NCT00553475
- Testing
- pregabalin
- Where
- 49 sites in Japan
- Volunteers
- 314 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathies, Neuralgia
Pregabalin Peripheral Neuropathic Pain Study
To evaluate the efficacy of pregabalin, using a flexible, optimized dose schedule with dose adjustment based on Daily Pain Rating Scale (DPRS), compared to placebo in subjects with peripheral neuropathic pain.
- Trial name
- NCT00141219
- Testing
- pregabalin
- Where
- 10 sites in South Korea
- Volunteers
- 241 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Retinopathy
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).
- Trial name
- NCT05038020
- Testing
- AKST4290
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alkahest, Inc.